EP Patent

EP2705840A1 — Use of rifapentine in the treatment and/or prevention of active tuberculosis disease

Assigned to Sanofi SA · Expires 2014-03-12 · 12y expired

What this patent protects

The invention relates to new doses and regimens of rifapentine and use in the prevention/treatment of active tuberculosis disease or tuberculosis infection in patients infected with the human immunodeficiency virus (HIV) / acquired immune deficiency syndrome (AIDS) and treated wi…

USPTO Abstract

The invention relates to new doses and regimens of rifapentine and use in the prevention/treatment of active tuberculosis disease or tuberculosis infection in patients infected with the human immunodeficiency virus (HIV) / acquired immune deficiency syndrome (AIDS) and treated with a combined antiretroviral combination, a combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate.

Drugs covered by this patent

Patent Metadata

Patent number
EP2705840A1
Jurisdiction
EP
Classification
—
Expires
2014-03-12
Drug substance claim
No
Drug product claim
No
Assignee
Sanofi SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.